Findings

What do systematic reviews say?

8 questions · 8 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 37.5%GRADE not reported 0 · 0%Very low 1 · 12.5%Low 0 · 0%Moderate 4 · 50%High 0 · 0%

CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' vs ANTIPSYCHOTIC 'B' for

Behaviour: Cannabis use 3: Traces of cannabis breakdown products in urine ‐ medium term · patients with schizophrenia

CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' showed no clear difference in behaviour: Cannabis use 3: Traces of cannabis breakdown products in… compared with ANTIPSYCHOTIC 'B' for (moderate certainty).

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.8 [0.52, 6.22]
1 study · 16 participants
Moderate

CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' vs ANTIPSYCHOTIC 'B' for

**Mental state: Obsessive–Compulsive Drug Use Scale (OCDUS) (short‐term, higher=bad) ‐ short term Scale from: 0 to 44. · patients with schizophrenia

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Moderate

CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' vs ANTIPSYCHOTIC 'B' for

Global state: relapse ‐ medium term ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' vs ANTIPSYCHOTIC 'B' for

General functioning ‐ no clinically important change in general functioning · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' vs ANTIPSYCHOTIC 'B' for

Adverse effects: measured adverse events ‐ Simpson scale ‐ medium term Scale from: 0 to 40. · patients with schizophrenia

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 2 participants
Moderate

CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' vs ANTIPSYCHOTIC 'B' for

Leaving the study early ‐ medium term ‐ any reason · patients with schizophrenia

CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' showed no clear difference in leaving the study early: any reason ‐ medium term compared with ANTIPSYCHOTIC 'B' for (moderate certainty).

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.5 [0.19, 1.29]
1 study · 28 participants
Moderate

CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' vs ANTIPSYCHOTIC 'B' for

Satisfaction with treatment ‐ medium term ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RISPERIDONE vs OLANZAPINE

Substance use: 1. Reduction of cannabis use‐change data (number of joints smoked/week) · people with both severe mental illness and substance misuse

1 finding from 1 review

Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low